Open Access Research Article Article ID: IJCEM-3-125

    Protein S100A8/A9: A Potential New Biomarker for Pancreatic Diseases

    El Gammal AT, Sturm JH, Pinnschmidt HO, Hofmann BT, Bellon E, et al

    Objectives: S100A8/A9  expression  has  been  linked  to  carcinogenesis  and  inflammation.We hypothesized  that  S100A8/A9  protein  serum  levels  are  a  useful  stratification  marker  for  patients  with pancreatic  ductal  adenocarcinoma  (PDAC),  intraductal  papillary  mucinous  neoplasm  (IPMN)  or  chronic pancreatitis (CP).

    Methods: S100A8/A9 serum levels were analysed in PDAC, CP and IPMN patients and compared to S100A8/A9 healthy donor controls (HD) using ELISA. S100A8/A9 levels and clinical data were statistically analysed.

    Results: Out  of134  patients  included,  84  were  diagnosed  with  PDAC  (46%),  30  patients with  IPMN  (16%) and 20 patients with CP (11%), 50 patients were HD (27%). When compared to HD (343.3 ng/ml), S100A8/A9 serum concentration was elevated in PDAC (402.0 ng/ml, p = 0.001) and CP patients (426.51 ng/ml p < 0.001). Also, S100A8/A9 levels were elevated in PDAC compared to IPMN group (369.0 ng/ml p  =  0.026)  and  in  CP  compared  to  IPMN  group  (p  =  0.001).  A  multivariate  model  including  age,  gender, leukocyte levels, C-reactive protein (CrP), S100A8/A9 and CA 19-9 concentrations reported a diagnostic sensitivity of 74.8%.

    Conclusion: S100A8/A9 serum levels are increased in patients with PDAC, CP, and IPM might be useful to distinguish malignant and inflammatory diseases from normal and non-malignant pathological conditions.


    Published on: Sep 19, 2017 Pages: 23-28

    Full Text PDF Full Text HTML DOI: 10.17352/ijcem.000025
    Get Citation Base Search Scilit OAI-PMH ResearchGate GrowKudos CrossMark

    Global Views

    Case Reports

    Peertechz Tweets

    Pinterest on IJCEM